RT Journal Article
SR Electronic
T1 Sex- and Gender-specific Risk Factors of Post-COVID-19 Syndrome: A Population-based Cohort Study in Switzerland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.30.21259757
DO 10.1101/2021.06.30.21259757
A1 Gebhard, Caroline E.
A1 Sütsch, Claudia
A1 Bengs, Susan
A1 Deforth, Manja
A1 Buehler, Karl Philipp
A1 Hamouda, Nadia
A1 Meisel, Alexander
A1 Schuepbach, Reto A.
A1 Zinkernagel, Annelies S.
A1 Brugger, Silvio D.
A1 Acevedo, Claudio
A1 Patriki, Dimitri
A1 Wiggli, Benedikt
A1 Beer, Jürg H.
A1 Friedl, Andrée
A1 Twerenbold, Raphael
A1 Kuster, Gabriela M.
A1 Pargger, Hans
A1 Tschudin-Sutter, Sarah
A1 Schefold, Joerg C.
A1 Spinetti, Thibaud
A1 Dussault-Cloutier, Arnaud
A1 Henze, Chiara
A1 Pasqualini, Mina
A1 Sager, Dominik F.
A1 Mayrhofer, Lilian
A1 Grieder, Mirjam
A1 Tontsch, Janna
A1 Franzeck, Fabian
A1 Wendel Garcia, Pedro D.
A1 Hofmaenner, Daniel A.
A1 Scheier, Thomas
A1 Bartussek, Jan
A1 Chrobok, Leon
A1 Stähli, David
A1 Lott, Nicola
A1 Haider, Ahmed
A1 Grämer, Muriel
A1 Mikail, Nidaa
A1 Rossi, Alexia
A1 Zellweger, Nuria
A1 Opic, Petra
A1 Portmann, Angela
A1 Todorov, Atanas
A1 Pazhenkottil, Aju P.
A1 Messerli, Michael
A1 Buechel, Ronny R.
A1 Kaufmann, Philipp A.
A1 Treyer, Valerie
A1 Siegemund, Martin
A1 Held, Ulrike
A1 Regitz-Zagrosek, Vera
A1 Gebhard, Catherine
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.06.30.21259757.abstract
AB Background Evidence to date indicates that mortality of acute coronavirus disease (COVID-19) is higher in men than in women. Conversely, women seem more likely to suffer from long-term consequences of the disease and pronounced negative social and economic impacts. Sex- and gender specific risk factors of COVID-19-related long-term effects are unknown.Methods We conducted a multicentre prospective observational cohort study of 5838 (44.6% women) individuals in Switzerland who were tested positive for SARS-CoV-2 RNA between February and December 2020. Of all surviving individuals who met the inclusion criteria, 2799 (1285 [45.9%] women) completed a follow-up questionnaire.Findings After a mean follow-up time of 197±77 days, women more often reported at least one persistent symptom (43.0% vs 31.5%, p<0.001) with reduced exercise tolerance and reduced resilience being the most frequently reported symptom in both sexes. Critical illness (intermediate or intensive care unit admission) during acute SARS-CoV-2 infection (odds ratio[95%CI]: 4.00[2.66-6.02], p<0.0001 was a risk factor of post-COVID syndrome in both women and men. Women with pre-existing mental illness (1.81[1.00-3.26], p=0.049), cardiovascular risk factors (1.39[1.03-1.89], p=0.033), higher self-reported domestic stress levels (1.15[1.08-1.22], p<0.0001), and feminine gender identity (1.12[1.02-1.24], p=0.02) increased the odds of experiencing post-COVID syndrome. Conversely, obesity (1.44[1.03-2.02], p=0.034) increased the odds of post-COVID syndrome in men, but not in women. Being responsible for household work (men, OR 0.82[0.69-0.97], p=0.021), taking care of children/relatives (women, 0.90[0.84-0.96], p=0.002) or being pregnant at the time of acute COVID-19 illness (OR 0.48[0.23-1.01], p=0.054) was associated with lower odds of post-COVID syndrome.Interpretation Predictors of post-COVID syndrome differ between men and women. Our data reinforce the importance to include sex and gender to identify patients at risk for post-COVID syndrome so that access to care and early intervention can be tailored to their different needs.Evidence before this study We performed a PubMed search for studies investigating short- and long-term health sequelae in COVID-19 survivors. We included all studies published prior to May 30th, 2021. The search comprised the following terms: (COVID-19 OR SARS-CoV-2 OR Coronavirus disease 2019 OR 2019-nCoV) AND (post COVID OR long COVID OR survivor OR recover OR persistent OR follow up OR discharge OR long-term OR sequelae). Previous studies have reported a variety of symptoms in COVID-19 survivors from different countries such as China (Wuhan), the UK, and the U.S. Overall, these studies showed that a substantial burden of health issues spanning multiple organ systems is experienced by patients who survive after the acute phase of COVID-19. The most frequent symptoms reported after acute infection were fatigue, muscle weakness, sleep disturbances, headache, dyspnoea, anxiety, depression, and anosmia. Two studies indicate that women are overrepresented amongst post-COVID-19 syndrome patients suffering from fatigue, headache, dyspnoea, or anosmia. However, the representativeness of the studies and the explicitness of provided information were insufficient due to lacking variables and/or small numbers of cases and the short duration of follow-up. Sex-and gender-specific predictors of post-COVID-19 syndrome are currently unknown.Added value of this study In a large cohort study (n=2799) with long follow-up (mean follow-up 197±77 days), we investigated sex- and gender-specific predictors of post-COVID-19 health sequalae. Our data allow for identification of sex- and gender-specific predictors of post-COVID-19 syndrome. In a multivariable association model, post-COVID-19 syndrome was associated with severity of illness and number of symptoms during acute SARS-CoV-2 infection in both sexes, while pre-existing mental illness and cardiovascular risk factors were significant predictors only in women. Conversely, obesity was independently associated with post-COVID-19 syndrome in men, but not in women. Gender-related risk factors of post-COVID syndrome were feminine traits and higher amount of domestic stress, both increasing the odds of post-COVID-19 syndrome in women, while pregnancy during acute COVID-19 illness and responsibility for childcare protected women, and responsibility for household work protected men from experiencing post-COVID-19 syndrome.Implications of all the available evidence Evidence indicates that mortality from COVID-19 infection is higher in men than women. We provide evidence that female sex and gender is associated with long-term sequalae of COVID-19. Our data reinforce the importance of including gender to identify patients at risk for post-COVID-19 syndrome so that the functional return of both male and female COVID-19 survivors can be maximized.Competing Interest StatementCG has received research grants from the Novartis Foundation and speakers fees from Sanofi Genzyme, Switzerland outside of the submitted work. The University Hospital Zurich (CG, RRB, APP, MM, PAK) holds a research contract with GE Healthcare outside of the submitted work. CG and AM have received research grants from Bayer Pharmaceuticals outside of the submitted work. JCS and TS reports (full departmental disclosure) grants from Orion Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences Services GmbH, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Draeger AG, Teleflex Medical GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter, Astellas, Astra Zeneca, CSL Behring, Novartis, Covidien, Nycomed, and Phagenesis, outside of the submitted work. The money went into departmental funds, no personal financial gain applies. All other authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis project is funded by the Swiss National Science Foundation (Project #196140, to CG, CEG, and VRZ), the LOOP Zurich (CG, VRZ, UH) and an unrestricted research grant from the intensive care unit (ICU) research foundation of the University Hospital of Basel (CEG). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to the anonymized data in the study and share final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the responsible ethics committee of the Canton of Basel (EKNZ, ethics approval #2020-01311). Informed consent was obtained from all participants or their legal representative.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBased on the Business Administration System for Ethics Committees (BASEC) ethics approval, the non-anonymized raw data cannot be shared publicly. However, anonymised data that underlie the results reported in this article will become available to interested parties for non-commercial reasons, after the publication upon reasonable requests made to the corresponding author. Data requestors will need to sign a data access agreement.